State Street Corp Has $12.74 Million Holdings in Merus (NASDAQ:MRUS)

State Street Corp decreased its position in Merus (NASDAQ:MRUS) by 3.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 255,064 shares of the biotechnology company’s stock after selling 9,809 shares during the period. State Street Corp’s holdings in Merus were worth $12,743,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. HighTower Advisors LLC acquired a new stake in Merus in the 3rd quarter valued at approximately $358,000. Holocene Advisors LP raised its holdings in shares of Merus by 4.1% in the third quarter. Holocene Advisors LP now owns 1,637,988 shares of the biotechnology company’s stock valued at $81,834,000 after purchasing an additional 64,122 shares during the last quarter. Verition Fund Management LLC lifted its position in shares of Merus by 16.6% in the third quarter. Verition Fund Management LLC now owns 42,746 shares of the biotechnology company’s stock worth $2,136,000 after purchasing an additional 6,071 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Merus by 17.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company’s stock worth $4,207,000 after purchasing an additional 12,212 shares during the last quarter. Finally, Ally Bridge Group NY LLC grew its position in Merus by 19.1% in the third quarter. Ally Bridge Group NY LLC now owns 208,244 shares of the biotechnology company’s stock valued at $10,404,000 after purchasing an additional 33,400 shares in the last quarter. 96.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $85.00 price target on shares of Merus in a research report on Monday, December 2nd. Needham & Company LLC reiterated a “buy” rating and set a $85.00 target price on shares of Merus in a report on Monday, December 9th. Guggenheim restated a “buy” rating and issued a $109.00 price target (down from $111.00) on shares of Merus in a research note on Tuesday, December 3rd. The Goldman Sachs Group initiated coverage on Merus in a research report on Thursday, November 21st. They set a “buy” rating and a $73.00 price target on the stock. Finally, UBS Group started coverage on Merus in a report on Thursday, October 24th. They issued a “buy” rating and a $72.00 price objective for the company. One analyst has rated the stock with a sell rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Merus presently has a consensus rating of “Buy” and a consensus target price of $85.64.

Merus Trading Down 0.1 %

NASDAQ MRUS opened at $42.41 on Thursday. The company has a market cap of $2.90 billion, a price-to-earnings ratio of -10.74 and a beta of 1.07. The company has a 50 day moving average of $47.62 and a 200-day moving average of $50.98. Merus has a 1-year low of $27.11 and a 1-year high of $61.61.

Merus (NASDAQ:MRUS) last released its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The company had revenue of $11.77 million for the quarter, compared to analyst estimates of $9.11 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. On average, equities research analysts forecast that Merus will post -3.89 earnings per share for the current year.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.